AU2020229830A1 - Anti-CD6 antibody compositions and methods for treating lupus - Google Patents

Anti-CD6 antibody compositions and methods for treating lupus Download PDF

Info

Publication number
AU2020229830A1
AU2020229830A1 AU2020229830A AU2020229830A AU2020229830A1 AU 2020229830 A1 AU2020229830 A1 AU 2020229830A1 AU 2020229830 A AU2020229830 A AU 2020229830A AU 2020229830 A AU2020229830 A AU 2020229830A AU 2020229830 A1 AU2020229830 A1 AU 2020229830A1
Authority
AU
Australia
Prior art keywords
alcam
subject
soluble
sample
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020229830A
Other languages
English (en)
Inventor
Stephen Connelly
Chandra Mohan
Krishna POLU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Houston System
Equillium Inc
Original Assignee
University of Houston System
Equillium Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Houston System, Equillium Inc filed Critical University of Houston System
Publication of AU2020229830A1 publication Critical patent/AU2020229830A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020229830A 2019-02-26 2020-02-26 Anti-CD6 antibody compositions and methods for treating lupus Pending AU2020229830A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962810628P 2019-02-26 2019-02-26
US62/810,628 2019-02-26
US201962933294P 2019-11-08 2019-11-08
US62/933,294 2019-11-08
PCT/US2020/019990 WO2020176682A1 (en) 2019-02-26 2020-02-26 Anti-cd6 antibody compositions and methods for treating lupus

Publications (1)

Publication Number Publication Date
AU2020229830A1 true AU2020229830A1 (en) 2021-09-16

Family

ID=70009403

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020229830A Pending AU2020229830A1 (en) 2019-02-26 2020-02-26 Anti-CD6 antibody compositions and methods for treating lupus

Country Status (12)

Country Link
US (1) US20220143140A1 (cg-RX-API-DMAC7.html)
EP (1) EP3930751A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022521973A (cg-RX-API-DMAC7.html)
CN (1) CN113490511B (cg-RX-API-DMAC7.html)
AU (1) AU2020229830A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021016967A2 (cg-RX-API-DMAC7.html)
CA (1) CA3131299A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021010283A (cg-RX-API-DMAC7.html)
PH (1) PH12021551994A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109118XA (cg-RX-API-DMAC7.html)
WO (1) WO2020176682A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107077B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
IL303290A (en) * 2020-12-04 2023-07-01 Equillium Inc Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells
EP4533094A4 (en) * 2022-05-25 2026-05-06 Univ Houston System METHODS AND SYSTEMS FOR RISK STRATIFICATION AND BLADDER CANCER MANAGEMENT
TWI869873B (zh) * 2023-06-05 2025-01-11 中國醫藥大學 一種檢測一個體罹患單純復發性風濕病的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998172A (en) * 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
AU747898B2 (en) * 1997-03-03 2002-05-30 Bristol-Myers Squibb Company Monoclonal antibodies to human CD6
MY154819A (en) 2006-12-26 2015-07-31 Centro Inmunologia Molecular Pharmaceutical compositions with capacity to induce adoptosis in tumor cells for the diagnosis and treatment of the b-cell chroniclymphocytic leukemia
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
WO2012133047A1 (ja) * 2011-03-25 2012-10-04 コニカミノルタエムジー株式会社 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法
EP2726879B1 (en) * 2011-07-01 2022-10-19 Beckman Coulter, Inc. Requlatory t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
CA2866612C (en) * 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
US10620201B2 (en) * 2014-01-20 2020-04-14 Pad 4 Di Maria Adele Silvia Denegri S.A.S. In vitro method for predicting, diagnosing and monitoring in therapeutic follow up lupus nephritis
SG11201808625QA (en) * 2016-04-04 2018-10-30 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS
WO2017214452A1 (en) * 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
KR102514528B1 (ko) * 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법

Also Published As

Publication number Publication date
PH12021551994A1 (en) 2022-08-15
SG11202109118XA (en) 2021-09-29
JP2022521973A (ja) 2022-04-13
BR112021016967A2 (pt) 2021-11-23
MX2021010283A (es) 2021-09-30
ZA202107077B (en) 2023-07-26
CA3131299A1 (en) 2020-09-03
US20220143140A1 (en) 2022-05-12
WO2020176682A1 (en) 2020-09-03
CN113490511B (zh) 2024-07-09
EP3930751A1 (en) 2022-01-05
CN113490511A (zh) 2021-10-08

Similar Documents

Publication Publication Date Title
US20220143140A1 (en) Anti-cd6 antibody compositions and methods for treating lupus
KR101361905B1 (ko) 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
JP6999417B2 (ja) Ibdにおける治療標的及びバイオマーカー
KR102425676B1 (ko) T 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 t 세포 활성화 저해 물질의 스크리닝 방법
KR102605045B1 (ko) Il33 및 il1rl1을 코딩하는 유전자에서의 위험 대립유전자를 갖는 환자에서의 폐 질환의 치료 및 저해
KR20150010709A (ko) Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
CN104870013A (zh) 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂
EP2782599B1 (en) Administration of alpha4beta7 hetero-dimer-specific antibody
JP2023052360A (ja) 膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法
JP2021511019A (ja) 関節リウマチ(ra)の処置のための診断方法及び治療方法
KR20200033930A (ko) 체크포인트 억제제에 대한 예측성 말초 혈액 바이오마커
JP2024509360A (ja) がんにおける方法およびバイオマーカー
KR20250138273A (ko) 뇌척수액에서 바이오마커를 검출함으로써 다발성 경화증을 진단 및 치료하는 방법
WO2008079877A2 (en) Compositions and methods for the diagnosis and treatment of iron-related disorders
WO2018231339A2 (en) Anti-phosphotyrosinylated pd-1 antibodies and uses thereof
HK40052994A (en) Anti-cd6 antibody compositions and methods for treating lupus
US20250003986A1 (en) K17 as a biomarker for tumor response to immunotherapy
HK40052994B (en) Anti-cd6 antibody compositions and methods for treating lupus
WO2019199896A1 (en) Agonist antibodies against human cd137 in cancer that express mhc i
EP4384276A1 (en) Biomarkers for cd40 agonist therapy
US20220340974A1 (en) Method of Predicting Requirement for Biologic Therapy
WO2020178193A1 (en) Method of treatment of sarcoidosis
CA3160220C (en) Soluble cd28 levels during immunotherapy